SCHEMBL472518

SCHEMBL472518

Cc1ncoc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 2/20 0.47
IMPDH1 P20839 1/20 0.47
GSK3B P49841 1/20 0.45
KIF11 P52732 5/20 0.42
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
MAPK14 Q16539 1/20 0.39
DRD2 P14416 5/20 0.39
DRD3 P35462 5/20 0.39
KCNH2 Q12809 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GPR119 Q8TDV5 1/20 0.38
MAPT P10636 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1855319 0.80 NOTUM (0.51) IMPDH2DRD3KCNH2
SCHEMBL472455 0.79 MAPK14 (0.54) IMPDH2IMPDH1MAPK14
SCHEMBL15929467 0.79 IMPDH2 (0.50) IMPDH2IMPDH1GSK3BLMNAMAPK14
SCHEMBL27252606 0.79 MEN1 (0.45) GSK3BKIF11MAPK14MEN1KMT2A
SCHEMBL472653 0.79 GSK3B (0.45) GSK3BKIF11LMNATHRBMAPK14
SCHEMBL472422 0.78 TRPV4 (0.42) IMPDH2IMPDH1KCNH2
SCHEMBL472380 0.78 HEXA (0.46) GSK3BKIF11LMNATHRBMAPK14
SCHEMBL472468 0.78 KDM4E (0.44) KIF11DRD2DRD3KCNH2KMT2A
SCHEMBL24212616 0.78 MAPK14 (0.53) GSK3BKIF11MAPK14MEN1KMT2A
SCHEMBL472560 0.77 IMPDH2 (0.46) IMPDH2IMPDH1KIF11GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114450281-B Inhibitor compounds 辛塞拉治疗私人有限公司 2024-08-16 CN disclosed
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed
EP-4003986-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-06-01 EP disclosed
EP-2412372-A1 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases Abbott Laboratories (US) 2012-02-01 EP disclosed
US-7998993-B2 TRPV1 antagonists ABBOTT LABORATORIES (US) 2011-08-16 US disclosed
EP-2220059-B1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LAB (US) 2011-08-03 EP disclosed
EP-2220059-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN Abbott Laboratories (US) 2010-08-25 EP disclosed
US-20090124666-A1 TRPV1 ANTAGONISTS ABBOTT LABORATORIES (US) 2009-05-14 US disclosed
WO-2009055749-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LABORATORIES (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB IMPDH2 3370/4885IMPDH1 2476/4885GSK3B 605/4885
US-20090124666-A1 TRPV1 ANTAGONISTS TRPV1, TRPV2, TRPV3 IMPDH2 4461/4885IMPDH1 4147/4885GSK3B 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.